Skip to content

Surgical Protocol for Peri-Implantitis Treatment-4

Surgical Protocol for Peri-implantitis in Vertical Defect in Absence of Keratinised Tissue Using Chemical Decontamination With Chlorexidine and a CTG: a Randomized Clinical Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03977298
Enrollment
30
Registered
2019-06-06
Start date
2018-07-02
Completion date
2021-12-30
Last updated
2020-11-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peri-Implantitis

Keywords

peri-implantitis, CTG, Chlorhexidine, surgical treatment, Keratinised tissue

Brief summary

Peri-implant diseases are common post-restorative complications in implant rehabilitations and they occur with an incidence of 12-43%. Based on the available data in literature, the surgical therapy for peri-implantitis is effective in disease resolution. Surgical access to peri-implant lesions facilitates the removal of all granulation tissue from the defect area as well as debridement and decontamination of the exposed implant surface defect area. Different techniques have been used for implant surface decontamination during peri-implant surgery, including mechanical, chemical and laser treatments.

Detailed description

Peri-implantitis are defined as inflammatory diseases caused by bacterial biofilm around implant surface characterized by bleeding on probing, probing depth and eventually bone loss; if not successfully treated they may lead to implant loss. Based on the available parameters that have been reported in literature non surgical therapy doesn't seem to be effective on peri-implantitis. Therefore it is recommended to consider advanced therapies such as surgical interventions when non surgical peri-implant therapy fails to achieve significant improvements in clinical parameters. Numerous approaches have been used for implant surface decontamination during per-implant surgery, including mechanical, chemical and laser treatments. Conventional mechanical means don't seem to be effective on peri-implant diseases. In addition, the rough implant surface is a retentive factor for bacterial colonization and therefore makes implant surface difficult to debride. Another problem in maintaining implant health concerns the presence or absence of keratinised tissue around implant: if present, it seams to help the patient to maintain an optimal level of oral hygiene around implant and therefore the implant survival itself. The aim of the present randomized controlled clinical trial is to assess the influence of keratinised tissue around implant in improving clinical parameters. In particular, implant surface will be decontaminated mechanically with titanium curettes and chemically using chlorhexidine; after this the bone defect will be filled with bio-materlal and a CTG around tissue implant will be randomized.

Interventions

PROCEDUREChlorhexidine

Inflammatory tissue, excess cement or plaque deposits will be removed using titanium curettes and the implant surface will be cleaned by copious irrigation with sterile saline and surgical gauze soaked in chlorhexidine

PROCEDURECTG

CTG will be positioned in the buccal aspect of the peri-implant tissue

Sponsors

Università Vita-Salute San Raffaele
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Masking description

Single (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
Yes

Inclusion criteria

* presence of at least one screw-type titanium implant exhibiting bleeding and/or suppuration on probing combined with: 1. PPD ≥ 5 mm and bone loss ≥ 2 mm (compared to crestal bone levels at the time of placement of the reconstruction) 2. PPD ≥6 and bone loss ≥3 (not compared to crestal bone levels at the time of placement of the reconstruction) * single tooth and bridgework restorations without overhangs no evidence of occlusal overload (i.e. occlusal contacts revealed appropriate adjustment) * treated chronic periodontitis and proper periodontal maintenance care FMPS \< 20% * non-smoker or light smoking status in smokers (\<10 cigarettes per day) implant function time ≥ 1 year.

Exclusion criteria

* Patients with uncontrolled diabetes * patients with osteoporosis or under bisphosphonate medication, * pregnant or lactating women * patients with a history of radiotherapy to the head and neck region hollow implants * implant mobility * implants at which no position could be identified where proper probing measurements could be performed; * previous surgical treatment of the peri-implantitis lesions

Design outcomes

Primary

MeasureTime frameDescription
Bleeding on probing changesbaseline, 3, 6 and 12 months after treatmentchanges of bleeding on probing, evaluated as present if bleeding will be evident within 30 s after probing, or absent, if no bleeding will be noticed within 30 s after probing

Secondary

MeasureTime frameDescription
clinical attachment level changesbaseline, 3, 6 and 12 months after treatmentchanges in clinical attachment level, measured from CEJ to the tip of the probe
probing pocket depth changesbaseline, 3, 6 and 12 months after treatmentchanges in probing depth probing, measured from gingival margin to te tip of the probe
mucosal recession changesbaseline, 3, 6 and 12 months after treatmentchanges in mucosal recession, measured from CEJ to gingival margin
bone level changesbaseline, 3, 6 and 12 months after treatmentchanges in bone level at mesial and distal aspect, measured on periapical X-ray

Countries

Italy

Contacts

Primary Contactmarco clementini
mclementini@me.com0226432806

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026